STAAR Surgical Q1 net sales up 16% to $73.5M; raises FY2023 outlook to $348M

STAAR SURGICAL CO

2023-Q1 EPS reported $0.05 revenue$73,528,000

ICL sales of $70.6M up 20% YoY; ICL units also up 20%.
GAAP EPS $0.05 vs $0.19; adjusted EPS $0.18 vs $0.29.
Fiscal 2023 net sales outlook raised to $348M from $340M, implying 28% ICL growth.
Gross margin improved to 78.3% from 77.9%.
Cash & investments at $217.3M, down from $225.5M at Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported first quarter ended March 31, 2023 results: revenue $73.5 million, net income $2.7 million or $0.05 per diluted share, EPS $0.05 per diluted share. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $73.5 million
Net income: $2.7 million or $0.05 per diluted share
EPS: $0.05 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

in the filing unless specifically stated so therein . --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 STAAR Surgical Reports First Quarter 2023 Results Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y LAKE FOREST, CA, May 3, 2023 --- STAAR Surgical

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-23-017172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.